论文部分内容阅读
目的观察依折麦布(Ezetimibe)对高血脂患者血脂水平、血清超敏C反应蛋白(hs-CRP)及白细胞介素-6(IL-6)的影响。方法 2009年1月至2011年10月心内科就诊的高脂血症患者102例,给予依折麦布10mg,每晚1次,治疗8周,检测患者用药前后血脂和血清hs-CRP、IL-6水平,同时,检测用药前后的肝功能和肌损伤情况。结果治疗后,总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)较治疗前明显降低(P均<0.01),高密度脂蛋白胆固醇(HDL-C)较治疗前升高(P<0.05),甘油三酯较治疗前降低,但差异无统计学意义(P>0.05);hs-CRP、IL-6水平明显降低(P均<0.01)。未发现依折麦布有导致肝功能异常及肌肉损伤等副作用。结论依折麦布具有明确的调理血脂以及抗炎症反应作用,从而具有很好的抗动脉粥样硬化效应。
Objective To observe the effects of ezetimibe on serum lipids, serum hs-CRP and interleukin-6 (IL-6) in patients with hyperlipidemia. Methods From January 2009 to October 2011, 102 patients with hyperlipidemia were enrolled in this study. Ezetimibe 10 mg was given once a night for 8 weeks. The levels of serum lipids and serum hs-CRP, IL -6 levels at the same time, before and after testing the liver function and muscle damage. Results After treatment, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment (all P <0.01), while HDL-C was higher than before treatment 0.05). The triglyceride level was lower than that before treatment, but the difference was not statistically significant (P> 0.05). The levels of hs-CRP and IL-6 were significantly decreased (all P <0.01). No ezetimibe-induced side effects such as abnormal liver function and muscle damage were found. Conclusion Ezetimibe has a clear effect of regulating blood lipids and anti-inflammatory reactions, which has a good anti-atherosclerotic effect.